Purpose: To find an association of relative expression of hsa-miR-24-3p and hsa-miR-34a-5p molecules and CYP4F2 enzyme activity in blood plasma of stable angina pectoris (AP) patients'.Materials and Methods: MiRNA gene expression analysis was performed on total RNA extracted from blood plasma, using quantitative real-time polymerase chain reaction. CYP4F2 enzyme levels were determined using commercial ELISA kit. In total, 32 AP and 15 control samples were examined.Results: The relative expression of hsa-miR-24-3p and hsa-miR-34a-5p was upregulated by 4.4 (p = 0.0001) and 3.8 (p = 0.005) -fold in AP patient's blood plasma compared to control subjects. CYP4F2 enzyme level in blood plasma were 2.1 (p = 0.001) times lower in AP patients. Circulating hsa-miR-24-3p was negatively associated with CYP4F2 enzyme level (Spearman correlation coefficient rank r= -0.32; p = 0.03). Moreover, patients that were taking atorvastatin, had 1.5 (p = 0.04) times higher hsa-miR-24-3p expression in blood plasma.Conclusions. Our data suggest that hsa-miR-24-3p might have an effect on CYP4F2 activity during atherosclerosis.

中文翻译：

---

心绞痛中CYP4F2酶活性的新潜在调节剂：hsa-miR-24-3p和hsa-miR-34a-5p。

目的：寻找稳定型心绞痛（AP）患者血浆中hsa-miR-24-3p和hsa-miR-34a-5p分子的相对表达与CYP4F2酶活性的关系。使用定量实时聚合酶链反应，对从血浆中提取的总RNA进行了分析。CYP4F2酶水平使用商品化的ELISA试剂盒进行测定。总共检查了32个AP和15个对照样品。结果：hsa-miR-24-3p和hsa-miR-34a-5p的相对表达上调了4.4（p = 0.0001）和3.8（p = 0.005）-与对照组相比，AP患者血浆中的血红蛋白含量增加了3倍。AP患者的血浆中CYP4F2酶水平降低2.1（p = 0.001）倍。循环中的hsa-miR-24-3p与CYP4F2酶水平呈负相关（Spearman相关系数等级r = -0.32; p = 0.03）。此外，服用阿托伐他汀的患者血浆中hsa-miR-24-3p的表达高1.5倍（p = 0.04）。我们的数据表明，hsa-miR-24-3p在动脉粥样硬化期间可能对CYP4F2活性有影响。